ST. LOUIS, July 29, 2026
C2N Diagnostics, LLC announced that researchers in the United Kingdom are integrating its PrecivityAD2® blood test into the Alzheimer’s disease diagnostic care pathway through a collaboration with the Davos Alzheimer’s Collaborative (DAC). The initiative is designed to accelerate the diagnosis of Alzheimer’s disease and support earlier clinical decision-making in primary care as well as for patients awaiting specialist dementia assessments. The project is part of DAC’s Accurate Dx program, with Imperial College London serving as the United Kingdom’s only participating center alongside health systems in the United States, European Union, and Japan. Recruitment for the UK study began in May 2026, evaluating how advanced blood biomarker testing can improve the efficiency and accuracy of dementia diagnosis before referral to specialist clinics.
Blood Biomarker Testing Moves Into Primary Care
At the center of the initiative is the BEAD-PC (Blood Biomarkers for Early and Accurate Diagnosis of Alzheimer’s Disease in Primary Care) study, where participating general practitioners in North West London are using the PrecivityAD2® blood test alongside standard cognitive assessments before referring patients to dementia specialists at Imperial College Healthcare NHS Trust. The test is intended for individuals 50 years and older who present with mild cognitive impairment or dementia symptoms and is designed to detect amyloid plaques with high diagnostic accuracy. Patients whose blood test results indicate possible early-stage Alzheimer’s disease are referred to the Imperial Memory Unit at Charing Cross Hospital for comprehensive specialist evaluation. By integrating biomarker testing directly into primary care, researchers aim to shorten the time between the onset of symptoms and a confirmed diagnosis while reducing delays in specialist referrals.
Study Aims to Improve Alzheimer’s Diagnosis Across Healthcare Systems
Researchers believe the project could reshape how Alzheimer’s diagnostics are delivered throughout the UK National Health Service (NHS) and other healthcare systems worldwide. The study will generate evidence on the feasibility of incorporating high-performance blood biomarker testing into routine primary care appointments, addressing one of the most persistent challenges in dementia care—late diagnosis. Investigators highlighted that recent advances in blood biomarkers have demonstrated diagnostic sensitivity and specificity comparable to specialized imaging and cerebrospinal fluid testing, offering a less invasive and more accessible alternative for patients. Earlier identification of Alzheimer’s disease may also enable faster access to emerging disease-modifying therapies and improve long-term patient management.
Advertisement
Global Collaboration Strengthens Alzheimer’s Research
The United Kingdom study builds on C2N Diagnostics’ longstanding partnership with the Davos Alzheimer’s Collaborative, which first deployed the PrecivityAD2® blood biomarker in healthcare system preparedness studies across Brazil, Japan, Mexico, Scotland, and the United States in 2021. C2N stated that its diagnostic technologies have supported more than 200 Alzheimer’s disease research studies globally and have contributed to numerous clinical trials evaluating disease-modifying therapies. The company continues collaborating with leading pharmaceutical companies, academic institutions, healthcare organizations, and research foundations to advance blood-based diagnostics capable of improving early detection, clinical decision-making, and patient outcomes in neurodegenerative diseases.
Source: C2N Diagnostics, press release
